FTH · Faeth Therapeutics, Inc.
$32.34
+3.79 (+13.27%)
At close · Aug 14
Going-concern doubt
— cleared Aug 4, 2026
The latest filing no longer states the doubt (first flagged May 15, 2026).
View the 10-Q filed Aug 4, 2026Market Cap
$835.68M
Shares
25.84M
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2026-08-11 | Cambrian BioPharma Inc | 10% Stockholder | 130,142 | 2026-07-22 | Fidelity Brokerage Services LLC |
| 2026-04-29 | Cambrian BioPharma Inc | 10% Stockholder | 155,142 | 2026-04-29 | Fidelity Brokerage Services LLC |
| 2026-02-24 | Celebi John | Former Officer | 3,374 | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Peyer James | Fomer Director | 950 | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-01-27 | RINGO WILLIAM R | Former Director | 1,169 | 2026-01-27 | Fidelity Brokerage Services LLC |
| 2025-12-09 | Peyer James | Former Director | 841 | 2025-12-09 | Fidelity Brokerage Services LLC |
| 2025-12-04 | Cambrian BioPharma Inc | 10% Stockholder | 21,222 | 2025-12-04 | Fidelity Brokerage Services LLC |
| 2025-12-04 | Cambrian BioPharma Inc | 10% Stockholder | 5,844 | 2025-12-04 | Fidelity Brokerage Services LLC |
Showing 1–8 of 8 filings
Key facts
CIK
1829802
CUSIP
81728A207
13F (30d)
49 filings
47 filers
Visit website
Investor relations